Background: Observational epidemiological studies have shown that higher intakes of vitamins or antioxidants were inversely associated with the risk of esophageal cancer. However, randomized controlled trials (RCTs) have reported no preventive efficacy of vitamin or antioxidant supplements on esophageal cancer. This meta-analysis aimed to investigate the efficacy of vitamin and antioxidant supplements in the prevention of esophageal cancer as reported by RCTs. Methods: We searched PubMed, EMBASE, and the Cochrane Library in May 2013. Two authors independently reviewed and selected eligible articles based on predetermined selection criteria. Results: Of 171 articles searched from three databases and relevant bibliographies, 10 RCTs were included in the final analyses. In a fixed-effect meta-analysis of 10 trials, there was no efficacy of vitamin and antioxidant supplements in the prevention of esophageal cancer (relative risk [RR], 1.04; 95% confidence interval [CI], 0.86-1.25; I 2 =0.0%). Also, subgroup meta-analyses showed that vitamin and antioxidant supplements had no preventive efficacy on esophageal cancer both in the high risk (RR, 1.04; 95% CI, 0.85-1.28; n=4) and non-high risk (RR, 1.01; 95% CI, 0.65-1.56; n=6) groups for esophageal cancer. Further, subgroup meta-analyses revealed no preventive efficacy on esophageal cancer by type of methodological quality and type of vitamin and antioxidant supplements. Conclusions: Unlike observational epidemiological studies, this meta-analysis of RCTs suggests that there is no clinical evidence to support the efficacy of vitamin and antioxidant supplements in the prevention of esophageal cancer. (J Cancer Prev 2013;18:135 -143) 
INTRODUCTION
In the meantime, several randomized controlled trials (RCTs) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] MATERIALS AND METHODS
Data search
We searched PubMed, EMBASE, and the Cochrane Library in May 2013, by using keywords related to vitamin and antioxidant supplements and esophageal cancer in RCTs.
Also, the bibliographies of relevant articles were searched in order to locate additional studies. We used the following keywords for the literature search: "vitamin," "antioxidant," "beta-carotene," or "selenium; and "esophageal cancer."
Selection criteria
We included RCTs that reported the preventive efficacy of vitamin or antioxidant supplements on esophageal cancer.
The main outcome measure was cancer incidence.
Selection of relevant trials
Two evaluators (Dr. Myung SK, Dr. Yang HJ) independently screened all the studies searched from the three databases. We tried to contact the authors of the articles with insufficient data. From the trials included in the final analysis, we extracted the following data: study name, journal, country, duration of supplement treatment and follow-up period (years), population (project name), supplement interventions, relative risk (RR) with 95% confidence intervals (CI), and number of cancer/number of participants in each intervention group.
Main and subgroup analyses
We examined the efficacy of vitamin and antioxidant supplements administered singly or in combination with other vitamin or antioxidant supplements on esophageal cancer, compared with placebo administration in all 10 trials. Also, we evaluated those efficacy by type of vitamin or antioxidant supplements, methodological quality, and high risk or non-high risk groups for esophageal cancer.
Assessment of methodological quality
We also evaluated the methodological quality of the trials by using the Jadad scale. 16 This 5-point scale consists of randomization (2 points), double-blind (2 points), and follow-up (dropouts and withdrawals; 1 point) in the report of a RCT. A trial with the score of 2 or less was considered as having low-quality, and the one with the score of 3 to 5 was considered as having high-quality.
Statistical analyses
The pooled RR with 95% CI was calculated on the basis of both the fixed-and random-effects models; the MantelHaenszel method was used in the fixed-effects model, and the DerSimonian and Laird method was used in the random-effects model. We estimated heterogeneity (between-studies variability) using the Higgins I 2 statistic, which measures the percentage of total variation across studies due to heterogeneity rather than chance. 17,18 I 2 was calculated as follows:
where Q is Cochran's heterogeneity statistic and df is the degrees of freedom corresponding to it. Cochran's Q statistic was calculated as follows:
Q=∑ (θi-θp) where θi is the RR of each ith trial, θp is the pooled RR of all the trials, and wi is the inverse variance of each ith trial as a weight. Negative values of I 2 are set at zero so that I 2 ranges between 0% (no observed heterogeneity) and 100%
(maximal heterogeneity). We considered an I 2 value greater than 50% as indicating substantial heterogeneity. When there was no substantial heterogeneity, we reported the pooled estimate calculated based on the fixed-effects model. When there was substantial heterogeneity, we reported the pooled estimate calculated based on the random-effects model.
We estimated publication bias by using Begg's funnel plot and Egger's test. When the P-value was less than 0.05 by Egger's test, the presence of a publication bias was considered. We used the Stata SE version 10.0 software package (StataCorp, College Station, Texas, USA) for statistical analysis.
RESULTS

Selection of trials
A total of 171 articles were retrieved after searching three databases and relevant bibliographies ( Fig. 1 ). After excluding duplicated articles and reviewing articles based on those title and abstracts, we reviewed 24 articles with those full texts and then included 10 trials in the final analysis. We excluded 14 articles because of identical populations (n=7), insufficient data (n=4), and studies not relevant to our subject (n=3).
General characteristics of trials
A total of 126,828 subjects with the 70,959 vitamin and antioxidant supplement and 55,869 placebo groups from 10 RCTs. As shown in Table 1 RR, relative risk; CI, confidence interval; NIT, the nutrition intervention trial; NPC, the nutritional prevention of cancer study; HPS, the heart protection study; CARET, the beta-carotene and retinol efficacy trial; SUVIMAX, the supplemenatation en vitamines et mineraux antioxydants; WHS, the women's health study; ATBC, the alpha-tocopherol beta-carotene cancer prevention study. RR, relative risk; CI, confidence interval; NIT, the nutrition intervention trial; NPC, the nutritional prevention of cancer study; HPS, the heart protection study; CARET, the beta-carotene and retinol efficacy trial; SUVIMAX, the supplemenatation en vitamines et mineraux antioxydants; WHS, the women's health study; ATBC, the alpha-tocopherol beta-carotene cancer prevention study. 95% CI, 0.86-1.25; I 2 =0.0%) (Fig. 2) . There was no evidence of publication bias in the selected studies (Egger's test, P for bias=0.913; The Begg's funnel plot was symmetrical) (Fig.   3 ). Table 2 shows the methodological quality of trials based on the Jadad scale. Eight trials received 4 or higher points and were classified as having a high quality, whereas two trials received 3 points and were classified as having a low quality.
Methodological quality of trials
Subgroup meta-analyses by type of supplements
In the subgroup meta-analyses by type of supplements (Table 3 ).
Subgroup meta-analyses by type of quality and risk group
The subgroup meta-analyses by type of quality showed no preventive efficacy of vitamin and antioxidant supplements on esophageal cancer for both high quality (RR, 1.06; 95% CI, 0.87-1.28; n=8) and low quality (RR, 0.70; 95% CI, 0.31-1.61; n=2) trials. Similarly, no preventive efficacy was found in both high risk (RR, 1.04; 95% CI, 0.85-1.28; n=4) and non-high risk (RR, 1.01; 95% CI, 0.65-1.568; n=6) groups for esophageal cancer.
DISCUSSION
The current meta-analysis of RCTs found that there was 
NIT, the nutrition intervention trial; NPC, the nutritional prevention of cancer study; HPS, the heart protection study; CARET, the beta-carotene and retinol efficacy trial; SUVIMAX, the supplemenatation en vitamines et mineraux antioxydants; WHS, the women's health study; ATBC, the alpha-tocopherol beta-carotene cancer prevention study. Our findings were inconsistent with those of previously published epidemiological studies and a meta-analysis of epidemiological studies, which had reported that people with the highest levels of antioxidant intake such as vitamin C or beta-carotene had an about 50% lower risk compared to those with lower levels of intake. which is composed of equal amounts of the 8 different stereoisomers of alpha-tocopherol, is different from its natural form (RRR-alpha-tocopherol). 19 Also, the human body absorbs and excretes natural and synthetic vitamin E differently, and those biological activities are different. 19, 20 As for beta-carotene, experimental studies reported that beta-carotene might play a potential protective role against cancer initiation. 21 However, it may act as a prooxidant in the presence of chronic oxidative stress such as smoking; this may induce the oxidation of beta-carotene and DNA oxidative damage and finally lead to lung cancer. 18, 22 Third, eliminating reactive oxygen species by antioxidant supplementation might interfere with several essential defensive mechanisms like apoptosis and detoxification and unexpectedly increase mortality. 23 Last, antioxidant supplements might have interdependency and show those efficacy only when given in combination. 24 There are several limitations in our study. First, we were unable to include several recent RCTs 25, 26 because data for esophageal cancer were not reported. Second, the statistical power of the current meta-analysis is very low because the incidence of esophageal cancer is very low, compared with other types of common cancers. Further lager RCTs are needed to confirm our findings. Last, we were unable to apply our findings to healthy populations.
Of 10 trials, only two trials involved general healthy populations, while the remaining trials involved a history of certain diseases or high risk populations for esophageal cancer.
In summary, unlike observational epidemiological studies, the current meta-analysis of RCTs found that there is no clinical evidence to support the efficacy of vitamin and antioxidant supplements in the prevention of esophageal cancer.
